初治系统性红斑狼疮患者LLDAS与缓解的发生频率及预测因素
基于北京大学第一医院SLE队列218例初治患者、中位随访4.48年的研究,评估LLDAS与DORIS各缓解定义的可及性。结果显示87.2%达LLDAS、73.4%达LLDAS5、67.9%达临床RONT、43.1%达完全RONT,而临床ROFT与完全ROFT仅10.6%与8.3%。抗dsDNA阳性、RP和贫血与达LLDAS、LLDAS5或临床RONT时间延长显著相关。
要点
- 初治SLE中LLDAS较易达到,中位1.4年,可作为早期治疗目标
- 临床RONT约三分之二患者可达,中位2.6年,但完全RONT仅43.1%
- ROFT仅少数患者达到,目前不宜作为理想治疗目标
核心结论
- LLDAS是初治SLE可达到的早期治疗目标,RONT虽较难但约三分之二患者可实现,ROFT目前仅少数患者达到,可能不是理想的治疗目标。
研究设计与样本
- 研究纳入北京大学第一医院SLE队列中的初治患者,共218例,中位随访4.48年,估计达到各状态的时间及年度累积概率并识别预测因素。
主要发现
- 190例(87.2%)达到LLDAS,160例(73.4%)达到LLDAS5,148例(67.9%)达到临床RONT,94例(43.1%)达到完全RONT,23例(10.6%)达到临床ROFT,18例(8.3%)达到完全ROFT。
- 达到LLDAS、LLDAS5、临床RONT和完全RONT的中位时间分别为1.4、2.3、2.6和4.7年。
- 抗dsDNA阳性、RP和贫血与达到LLDAS、LLDAS5或临床RONT的时间延长显著相关。
关键数值与推荐
- LLDAS5定义为LLDAS且泼尼松剂量≤5 mg/天。
- DORIS包含四种定义:临床RONT、完全RONT、临床ROFT和完全ROFT。
临床怎么用
- 可将LLDAS作为初治SLE的早期治疗目标,对合并抗dsDNA阳性、RP或贫血者应预期达标时间更长并加强随访。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the attainability of Lupus Low Disease Activity State (LLDAS) and definitions of remission in SLE (DORIS) in a treatment-naïve cohort of SLE. METHODS: LLDAS5 was defined as LLDAS with a prednisone dose ≤5 mg/day. There were four definitions in DORIS: clinical remission on treatment (RONT), complete RONT, clinical remission off treatment (ROFT) and complete ROFT. The treatment-naïve patients from Peking University First Hospital SLE cohort were enrolled. The time to each state and their annual cumulative probabilities were estimated. The frequencies of patients who achieved each component of LLDAS or DORIS during follow-up were determined. The predictors of time to each state were identified. RESULTS: A total of 218 patients were included, with a median follow-up of 4.48 years. Respectively, 190 (87.2%), 160 (73.4%), 148 (67.9%), 94 (43.1%), 23 (10.6%) and 18 (8.3%) patients achieved LLDAS, LLDAS5, clinical RONT, complete RONT, clinical ROFT and complete ROFT. The median time to LLDAS, LLDAS5, clinical RONT and complete RONT were 1.4, 2.3, 2.6 and 4.7 years, respectively. Positive anti-dsDNA, RP and anaemia were significantly associated with prolonged time to LLDAS, LLDAS5 or clinical RONT. CONCLUSION: Our data confirmed that LLDAS is an attainable early treatment target for SLE. Though with more difficulty, RONT can be achieved in two-thirds of our patients. ROFT may not be an ideal treatment target at present as it is only attained in few patients.
引用
- Gao D, Hao Y, Mu L, et al. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus. Rheumatology (Oxford). 2020. PMID: 32337549. doi:10.1093/rheumatology/keaa120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。